A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- Conditions
- Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
- Interventions
- Drug: Placebo matching nerandomilast
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 400
- Registration Number
- NCT06806592
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic-Arizona, Scottsdale, Arizona, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT06806852
- Locations
- 🇺🇸
University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States
🇺🇸Norton Cancer Institute, Downtown, Louisville, Kentucky, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tabletsDrug: Synjardy 5 mg/1000 mg film-coated tablets
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 64
- Registration Number
- NCT06792968
- Locations
- 🇷🇺
State Budgetary Institution of Healthcare of Yaroslavl region "Yaroslavl Regional Clinical Narcological Hospital, Yaroslavl, Russian Federation
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT06791122
- Locations
- 🇺🇸
North County Clinical Research, Oceanside, California, United States
🇺🇸CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸Health Synergy Clinical Research, LLC, West Palm Beach, Florida, United States
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 456906 - Formulation ADrug: BI 456906 - Formulation BDrug: BI 456906 - Formulation C
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06772532
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach/Riß, Germany
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
- Conditions
- Geographic Atrophy
- Interventions
- Drug: Placebo-matching BI 1584862
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT06769048
- Locations
- 🇺🇸
Associated Retina Consultants, Gilbert, Arizona, United States
🇺🇸Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸Phoenix Retina Associates, Phoenix, Arizona, United States
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tabletsDrug: Synjardy® 5 mg/850 mg film-coated tablets
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 64
- Registration Number
- NCT06766500
- Locations
- 🇷🇺
State Budgetary Institution of Healthcare of Yaroslavl region "Yaroslavl Regional Clinical Narcological Hospital", Yaroslavl, Russian Federation
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06745284
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 142
- Registration Number
- NCT06745297
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
- Conditions
- Macular Degeneration, Age-relatedGeographic Atrophy
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT06722157
- Locations
- 🇺🇸
Associated Retina Consultants, Gilbert, Arizona, United States
🇺🇸Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸Phoenix Retina Associates, Phoenix, Arizona, United States